Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

- 1-9. (Canceled without prejudice).
- 10. (Previously amended) A compound having the formula:

wherein:

 R^1 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, (C_1-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl- $C(O)OR^5$, $C(O)NHR^3$, $C(O)NHR^3$, $C(O)NR^3R^3$, $C(S)NR^3R^3$ or (C_1-C_8) alkyl- $O(CO)R^5$;

 R^2 is H or (C_1-C_8) alkyl;

 R^3 and R^3 are independently (C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, (C₀–C₄)alkyl–(C₁–C₆)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, (C₀–C₈)alkyl–N(R^6)₂, (C₁–C₈)alkyl–O R^5 , (C₁–C₈)alkyl–O(CO) R^5 , or C(O)O R^5 ;

 $R^4 \text{ is } (C_1-C_8)\text{alkyl}, (C_2-C_8)\text{alkenyl}, (C_2-C_8)\text{alkynyl}, (C_1-C_4)\text{alkyl}-OR^5, \text{ benzyl}, \text{ aryl},\\ (C_0-C_4)\text{alkyl}-(C_1-C_6)\text{heterocycloalkyl}, \text{ or } (C_0-C_4)\text{alkyl}-(C_2-C_5)\text{heteroaryl};\\ R^5 \text{ is } (C_1-C_8)\text{alkyl}, (C_2-C_8)\text{alkenyl}, (C_2-C_8)\text{alkynyl}, \text{ benzyl}, \text{ aryl}, \text{ or } (C_2-C_5)\text{heteroaryl};\\ C_5)\text{heteroaryl};$

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and the * represents a chiral-carbon center.

2

11. (Original) A compound of claim 10, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CCH₂OCH₃, or

$$\sim$$
 CH₂ \sim Or \sim CH₂ \sim Q \sim R⁷,

wherein Q is O or S, and each occurrence of R^7 is independently H,(C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, halogen, (C₀–C₄)alkyl–(C₁–C₆)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, (C₀–C₈)alkyl–N(R^6)₂, (C₁–C₈)alkyl–OR⁵, (C₁–C₈)alkyl–O(CO)R⁵, or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 12. (Original) A compound of claim 10, wherein R^1 is $C(O)R^3$.
- 13. (Original) A compound of claim 10, wherein R¹ is C(O)OR⁴.
- 14. (Previously amended) A compound having the formula:

$$\begin{array}{c|c} & O & O \\ \hline & N & \\ \hline & N & \\ R^1 & \\ N & \\ H & \\ \end{array}$$

wherein:

 R^1 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, (C_1-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl- $C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^3$, $C(S)NR^3R^3$ or (C_1-C_8) alkyl- $O(CO)R^5$;

 R^2 is H or (C_1-C_8) alkyl;

 R^3 and R^3 ' are independently (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, (C_0-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl-O(CO)R⁵, or C(O)OR⁵;

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- (C_1-C_6) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heteroaryl; R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl; C_5 heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and the * represents a chiral-carbon center.

15. (Original) A compound of claim 14, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CCH₂OCH₃, or

$$\cdots$$
CH₂ , \cdots CH₂ or \cdots CH $\overset{R^7}{\underset{R^7}{\bigcirc}}$ $\overset{R^7}{\underset{Q}{\bigcirc}}$ $\overset{R^7}{\underset{R^7}{\bigcirc}}$,

wherein Q is O or S, and each occurrence of R^7 is independently H,(C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, halogen, (C₀–C₄)alkyl–(C₁–C₆)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, (C₀–C₈)alkyl–N(R^6)₂, (C₁–C₈)alkyl–OR⁵, (C₁–C₈)alkyl–O(CO) R^5 , or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

- 16. (Original) A compound of claim 14, wherein R^1 is $C(O)R^3$.
- 17. (Original) A compound of claim 14, wherein R¹ is C(O)OR⁴.
- 18. (Previously amended) A compound having the formula:

$$R^{1}$$
 R^{2}
 R^{2}
 R^{2}
 R^{2}
 R^{2}

wherein:

 R^1 is H, (C_1-C_8) alkyl, (C_3-C_7) cycloalkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_0-C_4) alkyl- (C_1-C_6) heterocycloalkyl, (C_0-C_4) alkyl- (C_2-C_5) heteroaryl, $C(O)R^3$, $C(S)R^3$, $C(O)OR^4$, (C_1-C_8) alkyl- $N(R^6)_2$, (C_1-C_8) alkyl- OR^5 , (C_1-C_8) alkyl- $C(O)OR^5$, $C(O)NHR^3$, $C(S)NHR^3$, $C(O)NR^3R^3$, $C(S)NR^3R^3$ or (C_1-C_8) alkyl- $O(CO)R^5$;

 R^2 is H or (C_1-C_8) alkyl;

 R^3 and $R^{3'}$ are independently (C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, (C₀–C₄)alkyl–(C₁–C₆)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, (C₀–C₈)alkyl–N(R^6)₂, (C₁–C₈)alkyl–O R^5 , (C₁–C₈)alkyl–O(CO) R^5 , or C(O)O R^5 ;

 R^4 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, (C_1-C_4) alkyl- (C_1-C_6) heterocycloalkyl, or (C_0-C_4) alkyl- (C_2-C_5) heteroaryl; R^5 is (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, or (C_2-C_5) heteroaryl;

each occurrence of R^6 is independently H, (C_1-C_8) alkyl, (C_2-C_8) alkenyl, (C_2-C_8) alkynyl, benzyl, aryl, (C_2-C_5) heteroaryl, or (C_0-C_8) alkyl- $C(O)O-R^5$ or the R^6 groups can join to form a heterocycloalkyl group; and the * represents a chiral-carbon center.

19. (Original) A compound of claim 18, wherein R¹ is H, (C₁-C₄)alkyl, CH₂OCH₃, CH₂CCH₂OCH₃ or

$$CH_2$$
, CH_2 or CH_2 Q R^7 ,

wherein Q is O or S, and each occurrence of R^7 is independently H,(C₁–C₈)alkyl, (C₃–C₇)cycloalkyl, (C₂–C₈)alkenyl, (C₂–C₈)alkynyl, benzyl, aryl, halogen, (C₀–C₄)alkyl–(C₁–C₆)heterocycloalkyl, (C₀–C₄)alkyl–(C₂–C₅)heteroaryl, (C₀–C₈)alkyl–N(R^6)₂, (C₁–C₈)alkyl–OR⁵, (C₁–C₈)alkyl–C(O)OR⁵, (C₁–C₈)alkyl–O(CO)R⁵, or C(O)OR⁵, or adjacent occurrences of R^7 can be taken together to form a bicyclic alkyl or aryl ring.

20. (Original) A compound of claim 18, wherein R^1 is $C(O)R^3$.

5 DCJD: 502187.1

- 21. (Original) A compound of claim 18, wherein R¹ is C(O)OR⁴.
- 22-39. (Canceled without prejudice).
- 40. (Previously canceled without prejudice).
- 41-47. (Canceled without prejudice).
- 48. (Previously canceled without prejudice).
- 49-52. (Canceled without prejudice).
- 53-56. (Previously canceled without prejudice).
- 57-100. (Canceled without prejudice).
- 101. (New) A compound of claim 10, which is: N-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-duhydro-1H-isoindol-4-yl-methyl]-acetamide; N-{[2-(2,6dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}cyclopropyl-carboxamide; 1tert-butyl-3-[2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4ylmethyl]-urea; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-3,3dimethylbutanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4yl]methyl}-propanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4yl]methyl}-3-pyridylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3dioxoisoindolin-4-yl]methyl}heptanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3dioxoisoindolin-4-yl]methyl}-2-furylcarboxamide; 2-amino-N-{[2-(2,6-dioxo(3piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}acetamide; N-{[2-(2,6-dioxo(3piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-thienylcarboxamide; N-{[2-(2,6dioxo(3-piperidyl))-1,3-dioxoindolin-4yl]methyl}(ethylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}butanamide; N-{[2-(2,6dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2-pyridylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}undecamide, N-{[2-(2,6dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}2-methylpropanamide; N-{[2-

6

(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} cyclopentylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} cyclohexylcarboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} (butylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} (propylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} [(methylethylamino)] carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} (octylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} (cyclopropylamino)carboxamide; or N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl} (diethylamino)carboxamide.

102. (New) A compound of claim 10, which is: [2-(2,6-dioxo-piperidin-3yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid tert-butyl ester; 4-(aminomethyl)-2-(2,6-dioxo(3-Piperidyl))-isoindoline-1,3-dione; [2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]-carbamic acid ethyl ester; [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl-methyl]carbamic acid benzyl ester; 2-(dimethylamino)-N-{[2-(2,6-dioxo(3-piperidyl))-1,3dioxoisoindolin-4-yl]methyl}acetamide; ethyl 6-(3N-{[2-(2,6-dioxo(3-piperidyl))-1,3dioxoisoindolin-4-yl]methyl}carbamoyl)hexanoate; 3-[(tert-butoxy)carbonylaminol-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}propanamide; 3amino-N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}propanamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}-2methoxyacetamide; (N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4yl]methyl}carbamoyl)methyl acetate; ethyl 2-[N-{[2-(2,6-dioxo(3-piperidyl))-1,3dioxoisoindolin-4-yl]methyl}carbamoyl)amino]acetate; 7-amino-N-{[2-(2,6-dioxo(3piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}heptanamide; N-{[2-(2,6-dioxo(3piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}benzamide; N-{[2-(2,6-dioxo(3piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}phenylacetamide; N-{[2-(2,6-dioxo(3piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(phenylamino)carboxamide; N-{[2-(2,6dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(benzylamino)carboxamide, 2-(2,6-dioxo-piperidin-3-yl)-4-{[(furan-2-ylmethyl)-amino-methyl}-isoindole-1,3dione; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxo-2,3-dihydro-1H-isoindol-4ylmethyl]-isonicotinamide; 2-(2,6-dioxo(3-piperidyl))-4-({[(cyclohexylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; 2-(2,6-

7 DCJD: 502187.1

dioxo(3-piperidyl))-4-({[(ethylamino)thioxomethyl]amino}methyl)isoindole-1,3-dione; 2-(2,6-dioxo(3-piperidyl))-4-({[(propylamino)thioxomethyl]amino} methyl)isoindole-1,3-dione; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(cyclopentylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}(3-pyridylamino)carboxamide; N-{[2-(2,6-dioxo(3-piperidyl))-1,3-dioxoisoindolin-4-yl]methyl}piperidylcarboxamide; or piperazine-1-carboxylic acid [2-(2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-amide.

- 103. (New) A compound of claim 14, which is: N-[2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-4-ylmethyl]-acetamide; N-{[2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}cyclopropylcarboxamide; or N-{[2-(2,6-dioxo(3-piperidyl))-1-oxoisoindolin-4-yl]methyl}(ethylamino)carboxamide.
- 104. (New) A stereoisomer of a compound of any one of claims 10, 14, 18, 101, 102, or 103.
- 105. (New) A racemate of a compound of any one of claims 10, 14, 18, 101, 102, or 103.